PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) announced it will host a business update webcast on Thursday, March 26, at 11:30 a.m. Eastern time, featuring Dr. Babar K. Rao, principal investigator of its SKNJCT-003 Phase 2 clinical trial, to discuss recent study results and company developments.
The company said the call will follow the expected filing of its fiscal year 2025 Form 10-K after market close on Wednesday.
Dr. Rao, a dermatologist and clinical researcher affiliated with Rutgers Robert Wood Johnson Medical School and Weill Cornell Medical College, will provide an independent assessment of data from the SKNJCT-003 trial.
The study is a randomized, double-blind Phase 2 trial evaluating doxorubicin delivered through Medicus’ SkinJect microneedle platform in patients with nodular basal cell carcinoma, a common form of skin cancer.
According to the company, the trial reported a 73% clinical clearance rate in patients receiving a 200-microgram dose of the drug at Day 57, compared with 38% in the device-only control group.
The same cohort showed 40% histological clearance, indicating the absence of cancer cells under microscopic examination, the company said.
The trial included a control arm using the microneedle device without drug delivery to assess the added effect of doxorubicin.
Medicus said the difference in outcomes between treatment and control groups supports the therapeutic contribution of the drug delivered through the platform.
The company also noted that some response in the control group may reflect tumor disruption or immune activation caused by the microneedle device itself.
Basal cell carcinoma is the most common cancer worldwide, and current treatment typically involves surgical removal.
Medicus is developing SkinJect as a potential non-surgical treatment option.
The March 26 call will include updates on financial performance, clinical data interpretation, and development plans for both the SkinJect and Teverelix programs.
Participants can pre-register at https://dpregister.com/sreg/10207261/10379bd1029 or access the webcast at https://event.choruscall.com/mediaframe/webcast.html?webcastid=DeCGoBHR.
Dial-in numbers are 833-890-6070 for U.S. and Canada participants and 412-504-9736 for international callers.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.